Splash Pharmaceuticals, Inc. is focused on developing innovative therapies targeting CD44, a cell surface protein implicated in various cancer and arthritis conditions. The company employs a novel approach to cancer therapy, leveraging its extensive experience and data accumulated over decades in the field. Their lead candidate, SPL-108, has shown promising results in terms of safety and efficacy through multiple clinical trials involving over 100 human subjects, indicating a strong potential for effective treatment options in oncology and arthritis.

The company's commitment to advancing its clinical-stage pipeline underscores its dedication to addressing unmet medical needs in these areas. By concentrating on CD44 targeting, Splash Pharmaceuticals aims to provide safer and more effective therapeutic solutions, contributing to the evolving landscape of cancer treatment and arthritis management. Their ongoing research and development efforts reflect a strategic focus on harnessing the biological mechanisms associated with CD44 to improve patient outcomes.

United States

Splash Pharmaceuticals is a privately held clinical stage oncology pharmaceutical company advancing innovative therapies against a novel and pivotal cancer target.  The lead therapy has completed multiple Phase I and II clinical trials with promising results.

Splash Pharmaceuticals

Company Details